Microbot Medical (MBOT) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 09, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-19871
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	288 Grove Street
Entity Address, Address Line Two	Suite 388
Entity Address, City or Town	Braintree
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02184
City Area Code	(781)
Local Phone Number	875-3605
Title of 12(b) Security	Common Stock
Trading Symbol	MBOT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,504,433
Entity Listing, Par Value Per Share	$ 0.01

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,465	$ 2,468
Marketable securities	3,997	3,917
Restricted cash	48	49
Insurance recovery receivable related to legal settlement and legal expenses		1,335
Prepaid expenses and other current assets	628	152
Total current assets	7,138	7,921
Property and equipment, net	122	146
Operating right-of-use assets	174	260
Total assets	7,434	8,327
Current liabilities:
Accounts payable	178	357
Lease liabilities	110	191
Legal settlement accrual		2,211
Accrued liabilities	1,053	1,027
Total current liabilities	1,341	3,786
Non-current liabilities:
Long-term lease liabilities	38	40
Total liabilities	1,379	3,826
Shareholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 15,965,633 and 11,707,317 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively.	161	118
Additional paid-in capital	90,231	83,884
Accumulated deficit	(84,337)	(79,501)
Total shareholders’ equity	6,055	4,501
Total liabilities and shareholders’ equity	$ 7,434	$ 8,327

Interim Condensed Consolidat_2

Interim Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	15,965,633	11,707,317
Common stock, shares outstanding	15,965,633	11,707,317

Interim Condensed Consolidated

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Research and development, net	$ (1,417)	$ (1,365)	$ (2,586)	$ (2,982)
General and administrative, net	(1,094)	(959)	(2,309)	(2,261)
Operating loss	(2,511)	(2,324)	(4,895)	(5,243)
Financing income, net	46	37	59	103
Net loss	$ (2,465)	$ (2,287)	$ (4,836)	$ (5,140)
Basic net loss per share	$ (0.17)	$ (0.25)	$ (0.33)	$ (0.60)
Diluted net loss per share	$ (0.17)	$ (0.25)	$ (0.33)	$ (0.60)
Basic weighted average common shares outstanding	14,846,584	9,198,806	14,451,279	8,609,325
Diluted weighted average common shares outstanding	14,846,584	9,198,806	14,451,279	8,609,325

Interim Condensed Consolidate_2

Interim Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2022		$ 80	$ 75,970	$ (68,761)	$ 7,289
Balance, shares at Dec. 31, 2022		7,890,628
Share-based compensation			412		412
Issuance of common stock upon exercise of warrants		$ 3	(3)
Issuance of common stock upon exercise of warrants, shares		240,000
Net loss				(2,853)	(2,853)
Balances at Mar. 31, 2023		$ 83	76,379	(71,614)	4,848
Balance, shares at Mar. 31, 2023		8,130,628
Balances at Dec. 31, 2022		$ 80	75,970	(68,761)	7,289
Balance, shares at Dec. 31, 2022		7,890,628
Net loss					(5,140)
Balances at Jun. 30, 2023		$ 118	83,251	(73,901)	9,468
Balance, shares at Jun. 30, 2023		11,707,317
Balances at Mar. 31, 2023		$ 83	76,379	(71,614)	4,848
Balance, shares at Mar. 31, 2023		8,130,628
Share-based compensation			349		349
Net loss				(2,287)	(2,287)
Issuance of common stock and warrants net of issuance costs		$ 35	6,523		6,558
Issuance of common stock and warrants net of issuance costs, shares	[1]	3,576,689
Balances at Jun. 30, 2023		$ 118	83,251	(73,901)	9,468
Balance, shares at Jun. 30, 2023		11,707,317
Balances at Dec. 31, 2023		$ 118	83,884	(79,501)	4,501
Balance, shares at Dec. 31, 2023		11,707,317
Share-based compensation			529		529
Net loss				(2,371)	(2,371)
Issuance of common stock and warrants net of issuance costs	[1]	$ 17	2,380		2,397
Issuance of common stock and warrants net of issuance costs, shares	[1]	1,685,682
Issuance of common stock relating to settlement agreement	[2]	$ 10	1,101		1,111
Issuance of common stock relating to settlement agreement, shares	[2]	1,005,965
Balances at Mar. 31, 2024		$ 145	87,894	(81,872)	6,167
Balance, shares at Mar. 31, 2024		14,398,964
Balances at Dec. 31, 2023		$ 118	83,884	(79,501)	4,501
Balance, shares at Dec. 31, 2023		11,707,317
Net loss					(4,836)
Balances at Jun. 30, 2024		$ 161	90,231	(84,337)	6,055
Balance, shares at Jun. 30, 2024		15,965,633
Balances at Mar. 31, 2024		$ 145	87,894	(81,872)	6,167
Balance, shares at Mar. 31, 2024		14,398,964
Share-based compensation			331		331
Net loss				(2,465)	(2,465)
Issuance of common stock and warrants net of issuance costs	[3]	$ 16	2,006		2,022
Issuance of common stock and warrants net of issuance costs, shares	[3]	1,566,669
Balances at Jun. 30, 2024		$ 161	$ 90,231	$ (84,337)	$ 6,055
Balance, shares at Jun. 30, 2024		15,965,633
[1]Net of issuance costs in the amount of approximately $ 333 328 52

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 328	$ 333
Net of issuance costs not paid	$ 52

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (4,836)	$ (5,140)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation of property and equipment	42	51
Interest income and unrealized gains from marketable securities, net		(35)
Share-based compensation	784	761
Changes in assets and liabilities:
Prepaid expenses and other assets	(215)	318
Other payables and accrued liabilities	(387)	(1,012)
Insurance recovery related to legal settlement and legal expenses received in cash	1,335
Legal settlement paid in cash	(1,100)
Net cash flows used in operating activities	(4,377)	(5,057)
Investing activities:
Purchases of property and equipment	(18)	(10)
Purchases of marketable securities	(5,120)	(3,194)
Proceeds from sales of marketable securities	2,540	1,000
Proceeds from maturities of marketable securities	2,500	3,789
Short term deposit		3
Net cash flows provided by (used in) investing activities	(98)	1,588
Financing activities:
Issuance of common stock and warrants, net of issuance costs	4,471	6,719
Net cash flows provided by financing activities	4,471	6,719
Increase (decrease) in cash, cash equivalents and restricted cash	(4)	3,250
Cash, cash equivalents and restricted cash at beginning of period	2,517	2,519
Cash, cash equivalents and restricted cash at end of period	2,513	5,769
Supplemental disclosure of cash flow information:
Cash received from interest	109	75
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities	37	20
Issuance expenses	52	160
Legal settlement settled through issuance of common stock	1,111
Accrued bonus settled through grant of stock-option awards	76
Deferred issuance expenses	$ 138

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,465)	$ (2,371)	$ (2,287)	$ (2,853)	$ (4,836)	$ (5,140)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

GENERAL

GENERAL	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL A. Description of business Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors Going Concern To date, the Company has not generated revenues from its operations. As of June 30, 2024, the Company had cash equivalents and marketable securities balance of approximately $ 6,462 Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. War in Israel On October 7, 2023, the State of Israel, where the Company’s operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to ongoing military operations and armed conflicts in the Gaza Strip. It continues to evolve and has since spread to northern Israel and threatens to spread to other Middle Eastern countries including Lebanon and Iran. These military operations and related activities are on-going as of the issuance date of these financial statements. The Company has considered various ongoing risks relating to the military operation and related matters, including: ● That some of the Company’s Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and ● A slowdown in the number of international flights in and out of Israel. The Company is closely monitoring how the military operation and related activities could adversely affect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the filing date of the Quarterly Report on Form 10-Q of which these financial statements are a part, the Company has determined that there have not been any materially adverse effects on its business or operations, but it continues to monitor the situation, as any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support the Company’s clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change. C. Unaudited Interim Condensed Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim condensed financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim condensed consolidated financial statements should be read in conjunction with the latest audited financial statements. Operating results for the six-month period ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company’s latest annual audited financial statements, except if noted below. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. Fair value of financial instruments The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of June 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,997 $ 3,997 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of June 30, 2024 and December 31, 2023. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance or market condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method for awards that qualify as “plain-vanilla” options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Segment Reporting In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and related disclosures.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the Israeli Innovation Authority (“IIA”) for participation in research and development since 2013 through June 30, 2024 totaling approximately $ 1,878 74 1,620,000 447 ® In addition, as a result of the agreement with CardioSert Ltd. (“CardioSert”) on January 4, 2018, Microbot Israel took over the liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530 In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $ 925 In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to 3.0 5 The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. On December 11, 2022, the Company received approval for a grant from the Ministry of Economy, in the amount of NIS 300,000 83 ® 50 3 ® B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to the Company’s Self-Cleaning Shunt (SCS) project and its TipCat assets in addition to certain technology relating to the Company’s LIBERTY ® 1.5 3.0 In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023, and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY ® C. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert (the “CardioSert Agreement”) to acquire certain of its patent-protected technology (the “Technology”). Pursuant to the CardioSert Agreement, Microbot Israel made aggregate payments of $ 300 6,738 74 As a result of its core-business focus program and its cost reduction plan enacted in May 2023, the Company terminated the CardioSert Agreement effective as of August 17, 2023 in accordance with its terms and ceased its research and development and commercialization efforts for, and maintaining, the Technology, which resulted in CardioSert triggering on March 3, 2024 its right to reacquire the Technology for nominal consideration. See also Note 5C below. D. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $ 10,000 E. Engagement letters with H.C. Wainwright: In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023 and on May 29, 2024, pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0 1.0 The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. F. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $ 8,000 ● Royalties at a rate of 3 ● Royalties at a rate of 1.5 Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01). G. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $ 6,750 On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit. Pursuant to the Settlement Agreement, the Company paid $ 2,154 1,100 1,005,965 The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company . As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a liability and an asset on its balance sheet totaling $ 2,211 1,335 1,100 235 1,111 1,335 1,100 1,005,965 H. Mona litigation: On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The amount of profits was estimated in the complaint to be approximately $ 468 On March 31, 2021, the Court entered a judgment against Mona and in favor of the Company in the amount of approximately $ 485 On August 22, 2023, the District Court dismissed the Section 10(b) counterclaim in its entirety. After the Company initiated efforts to execute on the $485 judgment against Mona (the “Judgment”), Mona urged the Court to decide the motion to vacate the 16(b) Judgment on the grounds that the Company purportedly lacks Constitutional standing to bring this case, which he originally filed prior to the final dismissal of his 10(b) counterclaim. On January 30, 2024, a Report & Recommendation was issued that the motion be denied, which the Court adopted in the entirety in an Order on March 5, 2024. Mona has purported to appeal that denial. The Company believes Mona’s purported appeal is untimely and substantively meritless. Mona’s appellate brief was filed on June 28, 2024. The Company’s opposition is due to be filed on September 26, 2024. The Court has permitted the Company’s ongoing execution efforts to continue notwithstanding Mona’s purported appeal of the Court’s denial of Mona’s subsequent motion to vacate the Judgment. As of May 10, 2024, Mona posted a bond in the full amount of the Judgment. I. Contingent bonus commitments based on future capital raising: During February 2024, the Compensation Committee of the Board of Directors of the Company approved certain bonuses contingent on future capital raising efforts. These bonuses, associated with the fiscal year ended December 31, 2023, are detailed as follows: The Company’s CEO is entitled to a contingent cash bonus of approximately $ 298 The first 50% of the CEO’s contingent bonus ($149) is payable upon the Company raising at least $3,000 in new funds by June 30, 2024. The remaining 50% ($149), payable upon the Company raising at least $6,000 in new funds by September 30, 2024 (cumulative, so if $3,000 is not raised by June 30, 2024 but the full $6,000 is raised by September 30, 2024, the full amount is payable). Other executives are entitled to an aggregate contingent total bonus of NIS 230,736 61 which is payable upon the Company raising at least $3,000 in new funds by September 30, 2024.

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
SHARE CAPITAL	NOTE 4 - SHARE CAPITAL A. Preferred investment options inducement On December 29, 2023, the Company entered into a preferred investment option exercise inducement offer letter with certain holders of existing (i) Series A preferred investment options to purchase 1,022,495 2.20 350,878 2.075 312,309 3.19 1,685,682 1.62 1,685,682 1.50 2,730 333 84,284 2.025 B. June 2024 Offerings On June 3, 2024, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of 1,566,669 0.01 1.50 2,350 328 3,133,338 1.50 The Company also issued to Wainwright or its designees preferred investment options to purchase up to 78,333 1.875 C. Equity component of settlement amount As part of the Settlement Agreement (refer to Note 3G above), the Company issued 1,005,965 D. Equity classification The common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity. The Company analyzed the accounting treatment for the series E and series F preferred investment options and concluded that they should be classified as equity. The Company analyzed the accounting treatment for the preferred investment options issued to Wainwright. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards. E. Employee Stock Option Grants In February 2024, the Company granted the CEO, certain executives and certain employees, fully vested options to purchase an aggregate of 130,000 1.2684 The Company also granted the CEO and other executives, options to purchase an aggregate of 132,500 1.25 8 In February 2024, the Company granted the CEO and certain employees and advisors, options to purchase an aggregate of 195,000 1.2684 three years 25 99 79,567 1.25

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 5 – SUBSEQUENT EVENTS A. Reinstatement of ATM The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $ 4,820 538,800 584 B. Contingent Bonus Payments In July 2024, the Compensation Committee of the Board of Directors of the Company approved the payment of the first 50 149 50 61 C. Return of CardioSert Assets In July 2024, Microbot Israel transferred the Technology back to CardioSert, for nominal consideration, pursuant to the terms of the CardioSert Agreement. As a result, Microbot Israel’s liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.
Fair value of financial instruments	Fair value of financial instruments The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of June 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,997 $ 3,997 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of June 30, 2024 and December 31, 2023.
Share-based compensation	Share-based compensation The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance or market condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted using the “simplified” method for awards that qualify as “plain-vanilla” options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.
Contingencies	Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. The Company carries liability insurance to mitigate its exposure to losses, including litigation losses. The Company records the estimated amount of expected insurance proceeds for litigation losses incurred as an asset (typically a receivable from the insurer) and offset to losses up to the amount of the losses incurred when the amount is determinable and approved by the insurance company.
Recently issued accounting pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Segment Reporting In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT	The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of June 30, 2024 Total Level 1 Level 2 Level 3 Money market mutual funds $ 3,997 $ 3,997 $ - $ - As of December 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 2,497 $ 2,497 $ - $ - Money market mutual funds 1,420 1,420 - - $ 3,917 $ 3,917 $ - $ -

GENERAL (Details Narrative)

GENERAL (Details Narrative) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of incorporation	Aug. 02, 1988
Cash equivalents and marketable securities	$ 6,462

SCHEDULE OF FINANCIAL ASSETS FA

SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT (Details) - Marketable Securities [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value	$ 3,997	$ 3,917
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		2,497
Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		1,420
Fair Value, Inputs, Level 1 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value	3,997	3,917
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		2,497
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value		1,420
Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Assets, fair value

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 03, 2024 shares

Feb. 29, 2024 USD ($)

Jan. 26, 2024 USD ($) shares

Oct. 06, 2022 USD ($)

Oct. 03, 2022

Mar. 31, 2021 USD ($)

Apr. 28, 2019 USD ($)

Jan. 04, 2018 USD ($) shares

Feb. 29, 2024 USD ($)

Jun. 30, 2012

Jun. 30, 2024 USD ($) shares

Mar. 31, 2024 USD ($) shares

Jun. 30, 2023 USD ($) shares

Jun. 30, 2024 USD ($) shares

Dec. 31, 2023 USD ($)

Jun. 30, 2024 ILS (₪)

Feb. 29, 2024 ILS (₪)

Dec. 11, 2022 USD ($)

Dec. 11, 2022 ILS (₪)

Jun. 10, 2021 USD ($)

Loss Contingencies [Line Items]

Net sales royalty percenatge

3%

Gross proceeds from cash fee percentage

7%

Gross proceeds from management fee percentage

1%

Stock issued during period, value, new issues

$ 2,022

[1]

$ 2,397

[2]

$ 6,558

Litigation settlement amount

$ 2,154

Settlement agreement liability

$ 2,211

Insurance recoverable

1,335

Settlement amount recovery

1,100

Legal expense

235

Non operating loss on legal settlement

$ 1,111

Joseph Mona [Member]

Loss Contingencies [Line Items]

Purchase price of plaintiffs

$ 485

Chief Executive Officer [Member]

Loss Contingencies [Line Items]

Contigent bonus

$ 298

$ 298

Contigent description

The first 50% of the CEO’s contingent bonus ($149) is payable upon the Company raising at least $3,000 in new funds by June 30, 2024. The remaining 50% ($149), payable upon the Company raising at least $6,000 in new funds by September 30, 2024 (cumulative, so if $3,000 is not raised by June 30, 2024 but the full $6,000 is raised by September 30, 2024, the full amount is payable).

Other Executives [Member]

Loss Contingencies [Line Items]

Contigent bonus

$ 61

$ 61

₪ 230,736

Contigent description

which is payable upon the Company raising at least $3,000 in new funds by September 30, 2024.

Common Stock [Member]

Loss Contingencies [Line Items]

Stock issued during period, value, new issues

$ 16

[1]

$ 17

[2]

$ 35

Number of share issued | shares

1,566,669

[1]

1,685,682

[2]

3,576,689

[2]

Device [Member]

Loss Contingencies [Line Items]

Royalties percentage

3%

Integrated Product [Member]

Loss Contingencies [Line Items]

Royalties percentage

1.50%

Securities Purchase Agreement [Member]

Loss Contingencies [Line Items]

Purchase price of plaintiffs

$ 6,750

Securities Purchase Agreement [Member] | Common Stock [Member]

Loss Contingencies [Line Items]

Number of share issued | shares

1,566,669

Litigation Settlement [Member]

Loss Contingencies [Line Items]

Payment for litigation settlement

$ 1,100

$ 1,100

Restricted common shares issued for legal settlement | shares

1,005,965

Insurance recovery amount

$ 1,335

Litigation Settlement [Member] | Common Stock [Member]

Loss Contingencies [Line Items]

Number of share issued | shares

1,005,965

1,005,965

Israeli Innovation Authority [Member]

Loss Contingencies [Line Items]

Grants receivable

$ 74

$ 83

₪ 300,000

Additional grant receivable

$ 447

$ 447

₪ 1,620,000

Israeli Innovation Authority [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Net sales royalty percenatge

3%

Israeli Innovation Authority [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Net sales royalty percenatge

5%

Israeli Innovation Authority [Member] | CardioSert Ltd [Member]

Loss Contingencies [Line Items]

Repayment of government grants

$ 530

Israeli Innovation Authority [Member] | Nitiloop [Member]

Loss Contingencies [Line Items]

Repayment of government grants

$ 925

Ministry of Economy [Member]

Loss Contingencies [Line Items]

Grants receivable

$ 50

$ 50

Technion Research and Development Foundation Limited [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Net sales royalty percenatge

1.50%

Technion Research and Development Foundation Limited [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Net sales royalty percenatge

3%

CardioSert Ltd [Member] | Technology [Member]

Loss Contingencies [Line Items]

Payment to acquire intangible assets

$ 300

Number of common shares issued for acquisition | shares

6,738

Number of common shares issued for acquisition, value

$ 74

H.C. Wainwright & Co. LLC [Member]

Loss Contingencies [Line Items]

Warrant issued, descriptions

The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering.

H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]

Loss Contingencies [Line Items]

Offering costs

$ 10,000

Stock issued during period, value, new issues

$ 8,000

Alliance Investment Management, Ltd. [Member]

Loss Contingencies [Line Items]

Litigation settlement

$ 468

2013 Through June 30, 2024 [Member] | Israeli Innovation Authority [Member]

Loss Contingencies [Line Items]

Revenue grants received

$ 1,878

[1]Net of issuance costs in the amount of approximately $ 328 52 333

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 03, 2024

Feb. 29, 2024

Dec. 29, 2023

Jun. 26, 2023

Jun. 06, 2023

Oct. 25, 2022

Feb. 29, 2024

Jun. 30, 2024

Mar. 31, 2024

Jun. 30, 2023

[2]

Jun. 30, 2024

Dec. 31, 2023

Subsidiary, Sale of Stock [Line Items]

Existing investment options

$ 2,730

Agent fees and other offering expenses

$ 333

Common stock, par value

$ 0.01

$ 0.01

$ 0.01

Total expenses

$ 8

Annual bonus

$ 99

Chief Executive Officer Executives and Employees [Member]

Subsidiary, Sale of Stock [Line Items]

Share price per share

$ 1.2684

$ 1.2684

Agggregate number of options granted

130,000

Chief Executive Officer and Other Executives [Member]

Subsidiary, Sale of Stock [Line Items]

Share price per share

1.25

$ 1.25

Agggregate number of options granted

132,500

Chief Executive Officer Employees and Advisors [Member]

Subsidiary, Sale of Stock [Line Items]

Share price per share

1.2684

$ 1.2684

Agggregate number of options granted

195,000

Stock option vested term

3 years

Chief Executive Officer [Member]

Subsidiary, Sale of Stock [Line Items]

Share price per share

$ 1.25

$ 1.25

Agggregate number of options granted

79,567

Compensation percentage

25%

Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,566,669

[1]

1,685,682

[2]

3,576,689

Common Stock [Member] | Securities Purchase Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,566,669

Share price per share

$ 1.50

Common stock, par value

$ 0.01

Common Stock [Member] | H.C. Wainwright & Co. LLC [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

78,333

Share price per share

$ 1.875

Common Stock [Member] | Litigation Settlement [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,005,965

1,005,965

Series A Preferred Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,022,495

Share price per share

$ 2.20

Series C Preferred Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

350,878

Share price per share

$ 2.075

Series D Preferred Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

312,309

Share price per share

$ 3.19

Existing Preferred Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,685,682

Share price per share

$ 1.62

Inducement Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

1,685,682

Share price per share

$ 1.50

Preferred Investment Option Exercise Inducement Offers Letter [Member] | H.C. Wainwright & Co. LLC [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

84,284

Share price per share

$ 2.025

Private Placement [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Gross proceeds

$ 2,350

Offering expenses

$ 328

Series F Preferred Investment Options [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Number of share issued

3,133,338

Share price per share

$ 1.50

[1]Net of issuance costs in the amount of approximately $ 328 52 333

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended
	Jul. 01, 2024	Aug. 09, 2024	Jul. 31, 2024	Feb. 29, 2024
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Contigent bonus				$ 298,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate offering price value	$ 4,820,000
Issuance of shares		538,800
Gross proceeds from issuance of common stock		$ 584
Subsequent Event [Member] | Cardio Sert [Member]
Subsequent Event [Line Items]
Aggregate amount			$ 530,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Contingent bonus percentage			50%
Contigent bonus			$ 149,000
Subsequent Event [Member] | Chief Financial Officer and Chief Technology Officer [Member]
Subsequent Event [Line Items]
Contingent bonus percentage			50%
Contigent bonus			$ 61,000